Thermo Fisher and Genovis collaborate on biotherapeutics

Serving science company Thermo Fisher Scientific has begun a collaborative project with Genovis, a provider of enzyme products for biological drug development, to develop end-to-end workflows for the preparation, characterisation and monitoring of novel and complex biotherapeutics using liquid chromatography-mass spectrometry (LC-MS).

Bringing together Thermo Fisher’s LC-MS technology with the enzyme-based sample preparation and analysis techniques of Genovis will enable the development of robust, automation-ready, magnetic bead and chromatography-based workflows for the streamlined analysis of biotherapeutics. Expertise from Thermo Fisher’s Global Customer Solution Centers will also help Genovis to determine optimal hardware/software configurations and suitable consumables for critical quality attribute (CQA) analysis of biotherapeutics during the research and development phase.

“With the shift toward large biological entities, companies are aiming to bring to market medicines with greater affinity and efficacy, but these medicines also present an additional level of analytical complexity,” said John Rontree, Senior Director, Global Marketing and Strategy, Pharmaceuticals and Biopharmaceuticals, Thermo Fisher Scientific. “By collaborating with Genovis, we plan to develop comprehensive workflows that provide robust and advanced solutions for preparing and assessing complex biotherapeutics.”

“We are excited to work with Thermo Fisher Scientific to continue our goal toward more automated analytical workflows,” said Genovis CEO Fredrick Olsson. “Through this collaboration we will be able to develop new products and workflows on world-class instrumentation together with experts from Thermo Fisher’s European Biopharma Customer Solution Center and serve the growing analytical needs of biopharma customers of both companies with meaningful innovations.”

Please follow us and share on Twitter and Facebook. You can also subscribe for FREE to our weekly newsletters and bimonthly magazine.